Mina Iskander, MD

@fouadsjaber Congratulations Dr. Jaber 🎉🎉

🌟 Grateful and honored to have been inducted into the prestigious, Alpha Omega Alpha Medical Honor Society 🩺✨. This recognition reflects the support and guidance of so many mentors, friends, and family who made this journey possible. 🥳 What made this more memorable and special is celebrating it with my mom @BCMDeptMedicine @bcmhouston @bcm_gihep #AOA #Meded #GITwitter @BCMCME @TexasGastros @SeragHashem @EndoscopyOthman @milenasuarez @BilalMohammadMD @Hassanghoz1 #MedED

Sometimes, you have to hit the absolute bottom to realize that the only way out is to look up. Your struggle is just a chapter, not the whole story. Keep the faith.

Met a new patient for the first time today and they told me: "You are so easy to be around." That is truly one of the best things you can hear. Building that level of comfort in a first meeting is what it’s all about #MedTwitter

@ebtapper What is the best alternative when terlipressin is not available then?

Octreotide for hepatorenal syndrome is an expensive placebo In this small study, 1 in 6 patients treated with midodrine and octreotide had renal recovery This number is consistent with prior studies. It is dismal.

New year, new chapter. Be proud of how far you’ve come. It’s a journey, not a race. #HappyNewYear2026

@DrAhmedSalem2 @CleveClinicFL @Alomari_MD @ElfertKhaled @HazemAbosheaish @MouenKhashab @Eldesouki_mo @BakheetMd @SherifElhanafi @AmerGastroAssn @AmCollegeGastro @WaelMoh14093823 Mbrooook Dr Ahmed 🎊🎊

✨ Some dreams take years. Some take a village. 🤍 Today both came true. 🙏🌱 🩺 I matched in Gastroenterology at @CleveClinicFL 🎉🏥 🌟 Special thanks to my compass 🧭, my mentor🧭@Alomari_MD your guidance changed everything ❤️ 🤍 Grateful beyond words to every mentor 🤝✨❤️

@DrGlombicki Congratulations 🎉 👏🏻

Honored & ready to get to work.

Congrats to all my brilliant colleagues and friends who matched in every subspecialty! I didn’t match this cycle, but I’m incredibly proud of my journey so far and excited for the path ahead. Onward! #GIFellowship

@AbuassiMoe @EndoAthlete @docbraymd @DrHSKalsi @Badi_Rawashdeh Congratulations 🎉🎉

A dream came true - I matched into GI at Medical College of Wisconsin! 🌟 So grateful for my mentors, family, and friends who made this journey possible. Dr. Yaseen Perbtani @EndoAthlete @docbraymd #GIMatch #GI #MCW #NRMP

📢Anyone caring for patients with alcohol-associated liver disease! This one-pager summarizes the @AASLDtweets guideline on ALD. It is a must-have for all residents, hospitalists, and GI Fellows! @LiverFellow @geneyim #MedEd

@MelnaggarM @Zainab5003 @IKhattib Congratulations 👏🏻👏🏻

Grateful and blessed to receive the ACG Outstanding Research Award at #ACG2025 in Phoenix, Arizona! 🌟 This achievement wouldn’t be possible without our amazing team of dedicated Drs @Zainab5003 @IKhattib, Mark Nasseem, Ahmed Bahnasy, Mohamed Yasser Elnaggar, Basant Elsayed, Ahmed Ahmed, Areeba Mehmood. Special shoutout to Dr.@Zainab5003 for exceptional skills and commitment. 🙌 @AmCollegeGastro #ACG2025 #ResearchExcellence

@clivejmiranda A great senior makes all the difference! not only for the learning but for actually enjoying the experience.

☕️ Good morning from Day 4 of #ACG2025 Entering GI fellowship is scary. It’s brand new, uncharted territory You’ll never forget your first senior fellow who holds your hand during scopes, shows you around the hospital, and will pick up your anxious phone calls at 2am @MohammedQasswal was that for me and now he plays rodeo during his off-days in Houston 🤠 So good seeing you in Phoenix 🏜️♥️ #FutureOfGI #GITwitter

Presented our meta-analysis on posterior pericardiotomy safety outcomes in CABG and discussed IVUS vs Angiography-guided PCI in Left Main Disease. Heard Dr. Amanda Vest speak on preload dependence and geometric vulnerability in right heart failure. Experienced stunning Chicago skyline views and engaged in inspiring conversations with brilliant minds!! All in all, a fabulous day at #CHEST2025 🌇🫁🫀😇 @accpchest

Interesting findings, are you with or against sweeteners? #sugar #GI

@clivejmiranda @dbrennerGIMD @NMGastro @NorthwesternMed I really enjoy attending talks by Dr. Brenner. I definitely learn alot.

🙏🏻 Thank you @dbrennerGIMD for a fantastic talk on tenapanor and your 🔑 tips on managing #IBS patients A phenomenal storyteller as always! 💫 Come to Omaha more often. You’re just down the road and the 🥩🥩 are irresistible #GITwitter #MedTwitter @NMGastro @NorthwesternMed

🚨 A Pill for Obesity? The First Oral (Non-Peptide) GLP-1 Delivers Good Results - - - 📊 Phase 3 ATTAIN-1 trial of orforglipron (oral GLP-1 agonist): 🔹 −11.2% weight loss at 72 weeks with highest dose vs. −2.1% with placebo 🔹 >50% of patients hit ≥10% weight loss 🔹 1 in 5 patients achieved ≥20% weight loss 🔹 Improved waist size, blood pressure, triglycerides, and cholesterol 🔹 Side effects: Mostly mild/moderate GI symptoms; 5–10% discontinued 💡 Why this matters: GLP-1 injections changed obesity care—but an oral small-molecule pill could be the iPhone moment for accessibility, adherence, and global impact. 👉 The question now: Will oral GLP-1s make treatment as routine as a statin—or spark the same payer battles we see with injectables? 🔗nejm.org/doi/full/10.10…

#Alcohol is leaving a bigger mark on American health than many realize. New research shows that drinking drives the surge in liver disease and cancer deaths across the country. bit.ly/4nxtZ0n #livertwitter @juanpabloarab @OmarAdnanA @dami_gu

🚨 STEP UP Trial: Higher-dose semaglutide pushes weight loss closer to tirzepatide levels - - - The STEP UP phase 3b trial tested once-weekly semaglutide 7.2 mg vs. 2.4 mg and placebo in adults with obesity. Key results at 72 weeks: 🔹 –18.7% mean weight loss with 7.2 mg vs –15.6% with 2.4 mg vs –3.9% with placebo 🔹 +3% incremental benefit over 2.4 mg (p<0.0001) 🔹 Odds of achieving ≥25% weight loss were 2.4× higher with 7.2 mg than 2.4 mg Clinical relevance: This trial shows that semaglutide can reach ~19% body weight reduction on average — narrowing the gap with tirzepatide’s 21%+ outcomes from SURMOUNT-1. It provides a dose-escalation option for patients not meeting targets on 2.4 mg. Safety: GI side effects were more common (70.8% with 7.2 mg vs 61.2% with 2.4 mg), but serious adverse events were comparable across groups. 💡 Takeaway: Semaglutide 7.2 mg doesn’t surpass tirzepatide, but it meaningfully closes the gap—offering another escalation path in obesity care. #ObesityCare #GLP1 #Semaglutide #STEPUP #ObesityMedicine H/t @EricTopol 🔗thelancet.com/journals/landi…

This is one of my favorite studies. Regardless of liver disease severity or degree of portal hypertension: 🛑 alcohol ⬇️ decompensation AND ⬆️ survival ‼️Critical info for ALD: It is never too late to stop drinking🍸! @BenediktHofer @ReibergerThomas cghjournal.org/article/S1542-…

Differentiate ascites 1️⃣Diuretic-intolerant ➡️ hyponatremia, hypotension 2️⃣Diuretic-refractory ➡️ max spironolactone + furosemide = no natriuresis Urine Na/K check 🧪 ▪️Na > K + ↓ wt → sensitive ▪️Na < K + ↑/↔ wt → resistant ▪️Na > K + ↑/↔ wt → sensitive, poor diet